# Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

> **NCT01197469** · PHASE2 · COMPLETED · sponsor: **University of Dundee** · enrollment: 120 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Pulmonary Hypertension

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01197469
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-11-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197469, "Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01197469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*